Resistant to existing antibiotics, superbug-related infections worldwide result in thousands of deaths each year—an estimated 99,000 in the U.S. MRSA kills an estimated 19,000 people every year in the U.S., compared with the 17,000 who die from AIDS, according to the Centers for Disease Control.
"We are in a crisis situation," said Dr. Cesar Arias, an associate professor of infectious diseases at the University of Texas Health Science Center. "The World Health Organization says this is one of the top three health threats to the world in this century, and I can't argue with that," said Arias, who has researched and written extensively on superbugs.
Dr. G. Richard Olds, dean of the school of medicine at the University of California-Riverside, explains "Pharmaceutical companies like to push drugs in advertising to make money, and a patient often thinks if a doctor doesn't prescribe antibiotics he's a bad doctor," Olds said. "But the medical profession has to be precise when it comes to handing out drugs—we have to use them appropriately and for the right reasons,"
So the the world scientists are being mobilised to tackle the problem...ummm...no. Quite the opposite.
"We have a clear case of too many antibiotics being used and not enough new ones in the system to fight these bacteria," according to Alan Christianson, a specialist in naturopathic medicine. "We haven't had any new antibiotics in the pipeline over the past 10 years, and it takes time to get one in, so we're way behind the curve on this."
The large drugmakers Johnson & Johnson and AstraZeneca have said publicly that they have reduced or stopped research funding for new antibiotics, citing the costs. Developing more expensive drugs, such as one for HIV, is better for returns.
"These firms want to know that they will make an antibiotic that will work economically, and there is no guarantee," Christianson said. "There's a lot of trial and error to find the right one. There's really no money in antibiotics."
"We are in a crisis situation," said Dr. Cesar Arias, an associate professor of infectious diseases at the University of Texas Health Science Center. "The World Health Organization says this is one of the top three health threats to the world in this century, and I can't argue with that," said Arias, who has researched and written extensively on superbugs.
Dr. G. Richard Olds, dean of the school of medicine at the University of California-Riverside, explains "Pharmaceutical companies like to push drugs in advertising to make money, and a patient often thinks if a doctor doesn't prescribe antibiotics he's a bad doctor," Olds said. "But the medical profession has to be precise when it comes to handing out drugs—we have to use them appropriately and for the right reasons,"
So the the world scientists are being mobilised to tackle the problem...ummm...no. Quite the opposite.
"We have a clear case of too many antibiotics being used and not enough new ones in the system to fight these bacteria," according to Alan Christianson, a specialist in naturopathic medicine. "We haven't had any new antibiotics in the pipeline over the past 10 years, and it takes time to get one in, so we're way behind the curve on this."
The large drugmakers Johnson & Johnson and AstraZeneca have said publicly that they have reduced or stopped research funding for new antibiotics, citing the costs. Developing more expensive drugs, such as one for HIV, is better for returns.
"These firms want to know that they will make an antibiotic that will work economically, and there is no guarantee," Christianson said. "There's a lot of trial and error to find the right one. There's really no money in antibiotics."
1 comment:
GlaxoSmithKline was accused of paying off firms to delay the launch of cheap versions of its antidepressant treatment. Glaxo offered “substantial” payments to three companies – Alpharma, Generics and Norton Healthcare – to hold off from supplying rival medicines to Seroxat.
http://www.scotsman.com/business/management/glaxo-accused-of-pay-to-delay-deal-1-2902573
Post a Comment